What type of study is this?

December 8, 2025Blood

Distinct predictors of mortality and conduction disease in AL cardiac amyloidosis

View Full Paper

Ask AI

Bookmark

Chemotherapy significantly decreases the risk of conduction abnormalities in AL cardiac amyloidosis.
In patients aged 73 on average, 62 of 128 developed new conduction disease within 36 months.
Retrospective cohort study analyzed the impact of cardiac function and risk stratification on mortality.
Identification of distinct predictors for survival can improve management in amyloidosis patients.

No takes yet. Share an insight, caveat, or question.

Single-center cohort study identifies chemotherapy as a key factor for survival and conduction disease in AL cardiac amyloidosis.

Safdar et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark